Medsamic (Tranexamic Acid)

Tranexamic Acid is an antifibrinolytic used to manage bleeding in several clinical settings.

• Trauma or surgical bleeding: reduces peri‑operative blood loss by stabilising clots.
• Dental surgery bleeding: controls intra‑operative bleeding during oral procedures.
• Hereditary angioedema: helps prevent swelling episodes by limiting plasma‑derived bradykinin activation.
• Menorrhagia: decreases menstrual blood loss in women with heavy periods.

• Tranexamic Acid competitively inhibits the activation of plasminogen to plasmin by binding to lysine‑binding sites on plasminogen. This blockade reduces fibrinolysis, allowing formed fibrin clots to persist longer and thereby decreasing bleeding in various clinical situations.

Tranexamic Acid is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Vomiting: occasional emesis following administration.
• Diarrhea: loose stools may be reported.
• Headache: transient cranial discomfort.
• Dizziness: occasional light‑headedness.
• Injection site reactions: redness or mild pain at the infusion site.

Serious or Rare Side Effects

• Thromboembolic events: potential formation of clots in veins or arteries.
• Seizures: rare neurologic manifestation, especially with high doses.
• Visual disturbances: blurred vision or retinal changes.
• Hypersensitivity reactions: rash, urticaria, or anaphylaxis.
• Renal impairment: decreased kidney function in susceptible individuals.
• Hypotension: sudden drop in blood pressure during rapid infusion.

When using Tranexamic Acid, clinicians should observe several safety measures.

• Assess renal function: adjust use in patients with impaired kidneys.
• Monitor for thrombosis: watch for signs of clot formation, especially in high‑risk patients.
• Use caution in seizure history: increased risk of neurologic events.
• Avoid in active intravascular clotting: contraindicated when clots are present.
• Adjust dose in severe renal impairment: consider reduced dosing or alternative therapy.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Tranexamic Acid may interact with other medications, requiring careful management.

Major Interactions (Avoid)

• Procoagulant agents (e.g., activated factor VII): may excessively increase clot risk.
• Combined use with other antifibrinolytics (e.g., aprotinin): can amplify thrombotic potential.
• Hormonal contraceptives: may raise the likelihood of venous thromboembolism.

Moderate Interactions (Monitor Closely)

• NSAIDs: may counteract hemostatic benefit and increase bleeding.
• Antiplatelet drugs (e.g., clopidogrel): require monitoring of bleeding parameters.
• Warfarin or other anticoagulants: may need INR or coagulation monitoring.